BC
PTGX icon

Bayforest Capital’s Protagonist Therapeutics PTGX Stock Holding History

Bayforest Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Buy
+2,675
New +$279K 0.3% 50

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bayforest Capital's PTGX Position: Q2 2026 in Review

Bayforest Capital opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 2,675 shares worth $328K. The stake represents 0.3% of the portfolio and ranks #50 among its holdings.

343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bayforest Capital held 2,675 shares of Protagonist Therapeutics worth $328K as of Q2 2026.
  • Protagonist Therapeutics was a new Bayforest Capital position in Q2 2026.
  • Protagonist Therapeutics made up 0.3% of Bayforest Capital's portfolio in Q2 2026, its #50 holding.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.